新冠病毒德尔塔克戎变异株和BA.3变异株的中和作用 - Suppr

Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants.

作者信息

Evans John P, Qu Panke, Zeng Cong, Zheng Yi-Min, Carlin Claire, Bednash Joseph S, Lozanski Gerard, Mallampalli Rama K, Saif Linda J, Oltz Eugene M, Mohler Peter J, Gumina Richard J, Liu Shan-Lu

机构信息

Ohio State University, Columbus, OH

出版信息

N Engl J Med. 2022 Jun 16;386(24):2340-2342. doi: 10.1056/NEJMc2205019. Epub 2022 May 18.

DOI:10.1056/NEJMc2205019

PMID:35584183

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9165560/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d748/9165560/573c6b5cb41d/NEJMc2205019_f1.jpg

相似文献

Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants.

N Engl J Med. 2022 Jun 16;386(24):2340-2342. doi: 10.1056/NEJMc2205019. Epub 2022 May 18.

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.

Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312.

Spike Protein Antibodies Mediate the Apparent Correlation between SARS-CoV-2 Nucleocapsid Antibodies and Neutralization Test Results.

Microbiol Spectr. 2021 Sep 3;9(1):e0021821. doi: 10.1128/Spectrum.00218-21. Epub 2021 Jun 16.

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6.

N Engl J Med. 2022 Nov 17;387(20):1904-1906. doi: 10.1056/NEJMc2212117. Epub 2022 Oct 19.

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.

Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).

N Engl J Med. 2021 Jun 3;384(22):2161-2163. doi: 10.1056/NEJMc2104192. Epub 2021 Apr 7.

SARS-CoV-2 antibodies: Comparison of three high-throughput immunoassays versus the neutralization test.

Eur J Clin Invest. 2021 Jul;51(7):e13573. doi: 10.1111/eci.13573. Epub 2021 May 5.

Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.

MAbs. 2021 Jan-Dec;13(1):1953683. doi: 10.1080/19420862.2021.1953683.

Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.

Viruses. 2022 Jan 24;14(2):230. doi: 10.3390/v14020230.

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants.

N Engl J Med. 2022 Jun 30;386(26):2526-2528. doi: 10.1056/NEJMc2206725. Epub 2022 Jun 15.

引用本文的文献

Structural and Energetic Insights into SARS-CoV-2 Evolution: Analysis of hACE2-RBD Binding in Wild-Type, Delta, and Omicron Subvariants.

Int J Mol Sci. 2025 Apr 17;26(8):3776. doi: 10.3390/ijms26083776.

Emergence of Recombinant SARS-CoV-2 Variants in California from 2020 to 2022.

Viruses. 2024 Jul 27;16(8):1209. doi: 10.3390/v16081209.

Unraveling the Dynamics of Omicron (BA.1, BA.2, and BA.5) Waves and Emergence of the Deltacton Variant: Genomic Epidemiology of the SARS-CoV-2 Epidemic in Cyprus (Oct 2021-Oct 2022).

Viruses. 2023 Sep 15;15(9):1933. doi: 10.3390/v15091933.

The effects of amino acid substitution of spike protein and genomic recombination on the evolution of SARS-CoV-2.

Front Microbiol. 2023 Jul 25;14:1228128. doi: 10.3389/fmicb.2023.1228128. eCollection 2023.

Inferring Recombination Events in SARS-CoV-2 Variants In Silico.

Adv Exp Med Biol. 2023;1412:253-270. doi: 10.1007/978-3-031-28012-2_14.

Forecast for peak infections in the second wave of the Omicron after the adjustment of zero-COVID policy in the mainland of China.

Infect Dis Model. 2023 May 30;8(2):562-573. doi: 10.1016/j.idm.2023.05.007. eCollection 2023 Jun.

The Emergence of Hybrid Variants of SARS-CoV-2: Towards Hybrid Immunity.

Vaccines (Basel). 2023 Mar 30;11(4):764. doi: 10.3390/vaccines11040764.

A DNA Vaccine Encoding the Full-Length Spike Protein of Beta Variant (B.1.351) Elicited Broader Cross-Reactive Immune Responses against Other SARS-CoV-2 Variants.

Vaccines (Basel). 2023 Feb 22;11(3):513. doi: 10.3390/vaccines11030513.

Delta-Omicron recombinant escapes therapeutic antibody neutralization.

iScience. 2023 Feb 17;26(2):106075. doi: 10.1016/j.isci.2023.106075. Epub 2023 Feb 13.

Literature review on COVID-19 vaccine efficacy in the immunocompromised population, and possible implications to future vaccination in kidney transplant patients.

Front Med (Lausanne). 2023 Feb 2;10:1103699. doi: 10.3389/fmed.2023.1103699. eCollection 2023.

本文引用的文献

Evidence for SARS-CoV-2 Delta and Omicron co-infections and recombination.

Med. 2022 Dec 9;3(12):848-859.e4. doi: 10.1016/j.medj.2022.10.002. Epub 2022 Oct 20.

SARS-CoV-2 Delta-Omicron Recombinant Viruses, United States.

Emerg Infect Dis. 2022 Jul;28(7):1442-1445. doi: 10.3201/eid2807.220526. Epub 2022 May 12.

Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2.

Cell Host Microbe. 2022 Aug 10;30(8):1093-1102.e3. doi: 10.1016/j.chom.2022.04.014. Epub 2022 Apr 25.

Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events.

Signal Transduct Target Ther. 2022 Apr 26;7(1):138. doi: 10.1038/s41392-022-00992-2.

Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors.

JCI Insight. 2020 Nov 19;5(22):143213. doi: 10.1172/jci.insight.143213.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献